- Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
- Ipsen et Marengo Therapeutics annoncent la conclusion d’un second partenariat stratégique afin de faire progresser les actifs « T-Cell Engager » de précision de la plateforme TriSTAR de Marengo
- Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen nomme Josep Catllà, en qualité de Vice-Président Exécutif, Chief Corporate Affairs Officer
- Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
- Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
- Ipsen présente de nouvelles données sur l’efficacité à long terme d’elafibranor et la qualité de vie liée aux démangeaisons chez les patients atteints de cholangite biliaire primitive
- Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés
- Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
More ▼
Key statistics
On Friday, Ipsen SA (IPN:VIE) closed at 123.20, -3.98% below its 52-week high of 128.30, set on Sep 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 123.20 |
---|---|
High | 123.20 |
Low | 123.20 |
Bid | 121.70 |
Offer | 124.40 |
Previous close | 122.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 83.81m |
Free float | 35.97m |
P/E (TTM) | 16.15 |
Market cap | 10.01bn EUR |
EPS (TTM) | 7.39 EUR |
Annual div (ADY) | 1.20 EUR |
---|---|
Annual div yield (ADY) | 0.97% |
Div ex-date | May 30 2024 |
Div pay-date | Jun 03 2024 |
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼